Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Internal Medicine
•
Rheumatology
•
Rheumatoid Arthritis
•
General Rheumatology
•
JAK Inhibitors
•
Gastroenterology
•
General Hepatology
•
Cirrhosis
•
Hepatology
Do you avoid JAK inhibitors in patients with a history of liver disease including NAFLD or cirrhosis?
Related Questions
How do you approach managing nausea and GI side effects when initiating methotrexate?
Is there a risk of hepatitis C activation with rituximab in a patient who has a history of HCV treated with antivirals and who is in sustained viral response?
Can Xolair (omalizumab) be safely used in combination with biologics for patients with rheumatic disease?
How do you counsel patients who experience diarrhea from mycophenolate mofetil (Cellcept)?
Have you utilized JAK inhibitors in patients on dialysis?
Are there concerns with combining anti-IL5 biologics (mepolizumab or benralizumab) for severe asthma with other biologics for RA (e.g. TNFi)?
Are you comfortable trying a different JAK inhibitor in patients with prior JAK inhibitor allergy?
What is your approach to management of hyperlipidemia in patients taking JAK inhibitors?
How do you approach use of DMARDs and/or biologics for inflammatory arthritis in patients with a history of seizure disorder on anti-epileptic medications?
How would you manage a patient with highly active ankylosing spondylitis, iritis and Crohn’s, controlled with weekly adalimumab with co-morbid IgG4RD and intolerance of azathioprine due to elevated LFTs?
